News
Zai Lab receives U.S. FDA Orphan Drug Designation for small cell lung cancer treatment
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Zai Lab's ZL-1310, a potential highly active first-in-class DLL3 antibody-drug...
Takeda’s FRUZAQLA gains Health Canada market authorization for metastatic colorectal cancer
Health Canada has provided market authorization for Takeda Canada's FRUZAQLA (fruquintinib capsules), indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC)...
European Commission expands Jemperli plus chemotherapy approval to all adult patients with primary advanced...
The European Commission has approved GSK's Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or...
